Sponsored Links

Lymphology and Lymphedema
Title Filter     Display # 
# Article Title
1 Protalix BioTherapeutics Presents Data On The Company's Fabry Program And Oral Enzyme Gaucher Program With Experts In The Field Of Lysosomal Disorders
2 Breast Cancer Controversy Laid To Rest: Analyzing Sentinel Lymph Node For Further Tiny Tumors Has Little Prognostic Value
3 Determining Which Bladder Cancer Patients May Have Cancer Spread: Gene Test
4 New Research: Play Defense Against Rogue Cancer Gene WWP2 Spreading Culprit
5 Photodynamic Ablation Of Lymphatic Vessels And Intralymphatic Cancer Cells Prevents Metastasis
6 Three-Year Data From Phase 2 Trial Of Genzyme Gaucher Disease Oral Compound Suggest Sustained Or Further Improvement Across All Endpoints
7 Spinal Fluid Proteins Distinguish Lyme Disease From Chronic Fatigue Syndrome
8 Seeking Out Sentinel Lymph Nodes Of Breast Cancer Patients Using Microbubbles To Light The Way
9 Researchers Identify New, More Effective Tool In Diagnosing Breast Cancer And Melanoma In Sentinel Lymph Nodes
10 Validation Of A Gene Expression To Distinguish Metastasizing From Non-Metastasizing Head And Neck Cancers
11 Less Invasive Lymph-Node Biopsy Could Prevent Unnecessary Surgery For Patients With Early Stage Endometrial Cancer
12 Breakthrough Breast Cancer Report Finds Lymphoedema Services Are Not Meeting Breast Cancer Patients' Needs
13 Lymphoseek(R) (Tilmanocept) Meets All Endpoints In Neo3-09 Phase 3 Study
14 Survivors Of Childhood Cancer Are At Increased Risk For Ongoing Post-Therapy GI Complications
15 Researchers Receive NIH Grant For The Move Toward Clinical Trials Targeting The Lysosomal Storage Disease MPSIIIB
16 Ease The Aftermath Of Breast Cancer With New Imaging Technique
17 HemaQuest Pharmaceuticals Initiates Phase 2 Clinical Trial In EBV-Related Malignancies
18 Breast Cancer Survivors Don't Need To Be Afraid Of Air Travel: U Of A Study
19 Two-Year Data From Phase 2 Trial Of Genzyme's Eliglustat Tartrate For Gaucher Disease To Be Published In The Journal Blood
20 Shire Announces European Approval Of VPRIV(R) (velaglucerase Alfa) For The Treatment Of Type 1 Gaucher Disease
 
<< Start < Prev 1 2 3 4 5 Next > End >>
Page 1 of 5
Copyright (C) 2009 MedicalMarket.info